구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized)) Roche / Genentech·Lymphoma 183 trials·t½ 63 h |
|---|---|
Overview Program | Polatuzumab vedotin (Lyophilized) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | Lymphoma |
Overview Indication | Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin plus rituximab, cyclophosphamide, doxor |
Technology Linker | linker and subsequent carbonate coupling with camptothecin (CPT) |
MoA Biomarker | biomarkers for diagnosis and longitudinal disease monitoring |
PK/PD Half-life | 63 h |
PK/PD Species | Rabbit, Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology.. The topology of RNA therapeutics is emerging as a critical design dimension in precision oncology. Unlike linear mRNA, circular RNA (circRNA) lacks free ends, conferring exceptional resistance to exonuclease degradation and enabling sustained protein expression for days to weeks. Beyond their use as engi… |
Toxicology CRS | Reported |
Clinical Safety signal | Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology.. The topology of RNA therapeutics is emerging as a critical design dimension in precision oncology. Unlike linear mRNA, circular RNA (circRNA) lacks free ends, conferring exceptional resistance to exonuclease degradation and enabling sustained protein expression for days to weeks. Beyond their use as engi… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100.0% |
Clinical Result source | ClinicalTrials.gov NCT02611323 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02611323 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lyophilized (Polatuzumab vedotin, Polatuzumab vedotin (Lyophilized)) Roche / Genentech·Lymphoma 183 trials·t½ 63 h |
|---|---|
Overview Program | Polatuzumab vedotin (Lyophilized) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | Lymphoma |
Overview Indication | Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | vedotin plus rituximab, cyclophosphamide, doxor |
Technology Linker | linker and subsequent carbonate coupling with camptothecin (CPT) |
MoA Biomarker | biomarkers for diagnosis and longitudinal disease monitoring |
PK/PD Half-life | 63 h |
PK/PD Species | Rabbit, Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology.. The topology of RNA therapeutics is emerging as a critical design dimension in precision oncology. Unlike linear mRNA, circular RNA (circRNA) lacks free ends, conferring exceptional resistance to exonuclease degradation and enabling sustained protein expression for days to weeks. Beyond their use as engi… |
Toxicology CRS | Reported |
Clinical Safety signal | Circular Logic: Engineering Next-Generation Circular RNA Therapeutics for Precision Oncology.. The topology of RNA therapeutics is emerging as a critical design dimension in precision oncology. Unlike linear mRNA, circular RNA (circRNA) lacks free ends, conferring exceptional resistance to exonuclease degradation and enabling sustained protein expression for days to weeks. Beyond their use as engi… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100.0% |
Clinical Result source | ClinicalTrials.gov NCT02611323 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02611323 |
추천 비교
추천 비교